Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Anticoagulant treatment failure].

A Buliková1, M Penka

  • 1Oddĕlení klinické hematologie FN Brno. abulik@fnbrno.cz

Vnitrni Lekarstvi
|April 28, 2006
PubMed
Summary
This summary is machine-generated.

Treatment failure can occur with unfractionated heparin and vitamin K antagonists. Identifying causes like cancer or antiphospholipid antibodies is crucial for managing re-thrombosis during anticoagulant therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monoclonal gammopathy of clinical signifi cance with osteosclerotic lesions - a case report and a literature review.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2024
Same author

Increasing procoagulant activity of circulating microparticles in patients living with HIV.

Medecine et maladies infectieuses·2019
Same author

High Level of Circulating Microparticles in Patients with BCR/ABL Negative Myeloproliferative Neoplasm - a Pilot Study.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2019
Same author

Spontaneous retroperitoneal hematoma - our experience with surgical approach.

Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti·2019
Same author

Patterns in anticoagulant utilization in the Czech Republic during 2007-2017.

Journal of thrombosis and thrombolysis·2019
Same author

Biobanking - the First Step to Successful Liquid Biopsy Experiments.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2017
Same journal

Pharmacological profile of mepolizumab.

Vnitrni lekarstvi·2023
Same journal

Atypical form of Goodpasture's disease.

Vnitrni lekarstvi·2023
Same journal

Differentiated thyroid cancer - possible risks of treatment, suppressive therapy and adherence to current recommendations.

Vnitrni lekarstvi·2023
Same journal

Dyslipidemia - the known unknown.

Vnitrni lekarstvi·2023
Same journal

Internal comorbidities and complications of multiple sclerosis therapy - don't be caught off guard!

Vnitrni lekarstvi·2023
Same journal

Implications of highly suppressive treatment HIV infection.

Vnitrni lekarstvi·2023
See all related articles

Area of Science:

  • Pharmacology and Thrombosis Research
  • Clinical Medicine

Context:

  • Anticoagulant therapy, including unfractionated heparin and vitamin K antagonists, is essential for preventing and treating thrombosis.
  • Treatment failures, characterized by re-thrombosis, can occur despite adequate or inadequate anticoagulation.
  • Current anticoagulants have limitations that may contribute to their ineffectiveness.

Purpose:

  • To analyze the circumstances influencing unfavorable outcomes in anticoagulant therapy.
  • To distinguish between re-thrombosis during adequate and non-adequate therapy.
  • To identify the primary causes of anticoagulant treatment failure.

Summary:

  • Re-thrombosis during adequate anticoagulant therapy is often linked to underlying conditions such as cancer or antiphospholipid antibodies.

Related Experiment Videos

  • Identifying reasons for non-adequate anticoagulation can be challenging and requires careful documentation of re-thrombosis events.
  • Analysis of treatment failures necessitates distinguishing between therapy adequacy and identifying specific etiological factors.

    • Impact:

    • Highlights the need for thorough investigation into the causes of anticoagulant treatment failure.
    • Emphasizes the importance of objective documentation for understanding re-thrombosis events.
    • Suggests that novel anticoagulants under development may offer solutions for patients experiencing treatment failure.